Emerge Matrix

Emerge Matrix is a dual membrane, minimally manipulated, human amniotic and chorionic membrane product

INTENDED USES: Emerge Matrix serves as a natural, biologic barrier or wound cover. The typical patient population includes those with full thickness acute and

chronic wounds where a biologic barrier or wound cover is required.

CLAIMED BENEFITS: Emerge™ Matrix is a dual membrane, minimally manipulated, human amniotic and chorionic membrane product derived from placental tissue that retain the

structural and functional characteristics of the tissue. The final product is dehydrated, packaged in different size sheets, and terminally sterilized by irradiation. Emerge™ Matrix

consist primarily of extracellular matrix proteins and serve as a natural, biologic barrier or wound cover.

Emerge Matrix OPTIONS: Per Square Centimeter	
1x2cm	
2x2cm	
2x3cm	
2x4cm	
4x4cm	
4x6cm	
4x8cm	
7x7cm	
8x12cm	
9x20cm	

For a wound patient, the benefits of Emerge Matrix may include:

- **Protective Covering:** It serves as a wound cover or barrier, protecting the wound from the external environment.
- **Structural Support:** It is composed of extracellular matrix proteins and provides a natural, biological barrier or wound cover. It retains the structural and functional characteristics of the original tissue.

- **Healing Environment:** The product is designed to retain extracellular matrix proteins and may serve as a scaffold to support the body's regenerative processes. Placental tissue, from which it's derived, contains collagen fibers and other ECM proteins (like laminin, fibronectin, proteoglycans, hyaluronic acid).
- **Flexibility and Ease of Use:** The dehydrated allograft is flexible and can be easily positioned.
- **Convenient Storage:** It can be stored at ambient temperature.
- **Safety:** The donated tissues are collected from consented mothers undergoing full-term C-sections, and donors are screened according to FDA and AATB standards. The product undergoes a validated terminal sterilization process to ensure safety.

The addition of Skin Substitutes or Cellular or Tissue Based Products (CTPs) to certain wounds may afford a healing advantage over dressings and conservative treatments when these options appear insufficient to affect complete healing, after at least a 30 day period of comprehensive conservative therapy. There are currently a wide variety of bioengineered products available for soft tissue coverage to affect closure. • Human skin allografts are derived from donated human skin (cadavers) • Allogeneic matrices are derived from human tissue (fibroblasts or membrane) • Composite matrices are derived from human keratinocytes, fibroblasts and xenogeneic collagen • Acellular matrices are derived from xenogeneic collagen or tissue

For Medicare to cover this product, it needs to be ordered and applied by your clinician. A patient cannot purchase it directly from a Durable Medical Equipment (DME) store and receive reimbursement for it.

Key Features

	Composition: Animal-derived
	Composition: Human dermis with/without epidermis
	Composition: Human placenta or umbilical cord
	Composition: Viable (living) cells
	Configuration: Fenestrated/ meshed
	Configuration: Flowable
	Configuration: Sheet
	May apply on full-thickness wounds
	May apply over exposed tendon/ bone/ muscle
	May apply over infected tissue
	Processing: Cryopreserved
	Processing: Decellularized or irradiated
	Processing: Dehydrated

	Processing: Fresh (limited shelf life)
	Processing: Hydrated
	Processing: Minimally manipulated
	Shelf life: Greater than 2 years
	Storage: refrigeration needed
	Storage: room temp